Global Phenylketonuria Market Size To Grow USD 1121.01 Billion by 2030 | CAGR of 6.2%
April 20, 2023 07:45 ET
|
SPHERICAL INSIGHTS LLP
New York, United States , April 20, 2023 (GLOBE NEWSWIRE) -- The Global Phenylketonuria Market Size is to grow from USD 610.3 million in 2022 to USD 1121.01 million by 2032, at a Compound Annual...
Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
March 29, 2023 06:40 ET
|
Synlogic, Inc.
– Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – – Rare Pediatric Disease Designation granted for SYNB1934 for PKU and SYNB1353 for homocystinuria (HCU)...
Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
March 20, 2023 06:55 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, announced that positive data from the...
Synlogic To Present Three Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
March 07, 2023 06:57 ET
|
Synlogic, Inc.
– Podium presentation on Phase 2 phenylketonuria (PKU) data – – Poster presentations on Phase 1 homocystinuria (HCU) data and HCU preclinical data – CAMBRIDGE, Mass., March 07, 2023 (GLOBE...
Synlogic Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria (PKU)
January 19, 2023 06:58 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that SYNB1934 was granted...
Synlogic Provides Corporate Update and Outlook for 2023
January 05, 2023 06:58 ET
|
Synlogic, Inc.
Pivotal Phase 3 for SYNB1934 in phenylketonuria (PKU) to initiate in H1 2023 Rare Pediatric Disease Designation received for SYNB1353 for homocystinuria (HCU) Cash runway expected into H2 2024 ...
Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3
October 18, 2022 06:59 ET
|
Synlogic, Inc.
Positive results include clinically meaningful Phe reductions, with a 60% response rate and 42% reduction in plasma Phe among responders across the study population Consistent, positive measures of...
Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1618 for the Treatment of Phenylketonuria
May 24, 2022 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
FIXX NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Homology Medicines, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – FIXX
April 26, 2022 11:24 ET
|
The Rosen Law Firm PA
NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Homology Medicines, Inc. (NASDAQ: FIXX) between June...
ROSEN, A LONGSTANDING LAW FIRM, Encourages Homology Medicines, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – FIXX
March 31, 2022 17:15 ET
|
The Rosen Law Firm PA
NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...